ABSTRACT
INTRODUCTION
Urinary-tract infections (UTIs) are the second most common cause of community-acquired infections, with Escherichia coli being the most common causative pathogen [1] . The great majority of UTIs are easily manageable, although some patients experience frequent relapses [2] . Development of resistance is a Cefprozil and cefixime are antimicrobials introduced in the market more than two decades ago. Cefprozil is a cephem antimicrobial and cefixime is an orally available third-generation cephalosporin. Since enterobacteriaceae belong to their antimicrobial spectrum, both these antimicrobials are suggested for the management of UTIs [4, 5] . For many years, cefixime was considered an ideal alternative for patients with acute pyelonephritis switching from intravenous to oral therapy [5] . The application of both these agents in the therapeutic armamentarium against UTIs has been abandoned over the years, whereas their activity on urinary pathogens is not reported in studies published over the last 5 years. The emerging resistance of uropathogenic enterobacteriaceae to commonly prescribed antimicrobials [3] led us to conduct the current study to investigate the activity of cefprozil and cefixime against enterobacteriaceae pathogens from patients with community-acquired UTIs.
METHODS
This was a multicenter study that was conducted during the period November 2012 until April 2013 among patients admitted for urine culture into 10 different microbiology laboratories in Greece. The study was approved by the Ethics Committees of the Prefectures that the labs refer to. Inclusion criteria were: (a) written informed consent; (b) female gender; (c) age C18 years; (d) at least two of the following symptoms of acute cystitis, i.e., micturition, pain at urination and increased frequency of urination; (e) one Gram-negative isolate grown at quantity C10 5 cfu/ml from midstream urine culture; (f) uncomplicated cystitis; and (g) community-acquired UTI. 
RESULTS
A total of 747 isolates were collected belonging to the species of E. coli, Klebsiella pneumoniae and Proteus mirabilis (Fig. 1) . Overall prevalence of ESBL production was 6.7%. E. coli was the most common pathogen isolated from 85.7% of patients. Among E. coli isolates, 93.8% were non-ESBL producers and 6.2% were ESBL producers. Among K. pneumoniae isolates, 81.8% were non-ESBL producers and 18.2%
were ESBL producers. None of the P. mirabilis isolates were ESBL producers.
Against non-ESBL-producing E. coli, cefprozil was more active than ciprofloxacin (93.7% vs 80.2% of isolates inhibited, p\0.0001). This was not the case for cefixime (85.7% vs 80.2% of isolates inhibited, p 0.125) ( Table 1) .
Although the activity of cefprozil and cefixime was limited against ESBL-producing isolates, they were active against isolates resistant to ciprofloxacin (Table 2) .
DISCUSSION
Current results suggest that in an era of emerging antimicrobial resistance, cefprozil and cefixime retain good activity against enterobacteria from patients with community-acquired UTI. However, both antimicrobials are not active against isolates that produce ESBL. Both tested drugs are available for oral administration. Cefixime was studied instead of other oral third-generation . In our study, cefprozil inhibited E. coli at a rate significantly greater than ciprofloxacin; both cefprozil and cefixime retained good activity against ciprofloxacin-resistant isolates. As a consequence, they remain a good therapeutic alternative either for empirical treatment, in the case of high suspicion for ciprofloxacin-resistant pathogens, or when one ciprofloxacin-resistant pathogen is isolated from urine.
One huge emerging problem in the management of community-acquired UTIs is enterobacteria pathogens that are b-lactam-resistant through the production of ESBL. Current publications suggest that the prevalence of these isolates ranges between 2 and 6% in E. coli and it is higher in K.
pneumoniae [10, 12, 13] . These rates are in accordance with the 6.7% prevalence reported in the present study. Female gender, recurrent
UTIs and presence of comorbidities are the most common risk factors for the acquisition of these isolates [12, 13] . Our findings suggest that both cefprozil and cefixime have poor activity against these isolates and that they cannot be suggested for management. Their empirical use should not be considered when there is ESBL extended-spectrum b-lactamase, MBC minimum bactericidal concentration, MIC minimum inhibitory concentration a Susceptibility concentration breakpoint Table 2 Comparative susceptibility of 13 antimicrobials against urinary-tract pathogens in relation to resistance phenotype
K. pneumoniae The current study did not focus on epidemiological information of patients with UTIs caused by ESBL-producing isolates and ciprofloxacin-resistant isolates. This is because a previous large-scale epidemiological study in Greece has clearly shown the impact of previous antimicrobial consumption in the last 3 months as a risk factor for the emergence of these resistant isolates [3] . Major emphasis was given on the use of cefprozil and cefixime as alternative treatments for UTIs.
CONCLUSION
The results of the present study indicate that cefprozil and cefixime retain good activity against urine pathogens. According to our findings, they can be empirically used for management. Their use is particularly encouraged in the following cases: (a) UTIs with documented or high suspicion for implication of ciprofloxacin-resistant pathogens; and (b) UTIs by pathogens cross-resistant to other antimicrobials provided that they do not produce ESBL.
